Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Abcellera Biologics Inc's Business Segments
Abcellera Biologics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Research Fees
Total Revenue
$ 4
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Research Fees0%
- Licensing and Royalty Revenue8.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Research Fees | $ 12 | - |
| Licensing and Royalty Revenue | $ 0 | 8.4% |
Revenue by Product & Service Category - FY
- Research Fees97.7%
- Licensing and Royalty Revenue2.3%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Research Fees | $ 8 | 97.7% |
| Licensing and Royalty Revenue | $ 0 | 2.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Research Fees0%
- Licensing and Royalty Revenue8.4%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Research Fees | $ 12 | - |
| Licensing and Royalty Revenue | $ 0 | 8.4% |
Description of Abcellera Biologics Inc
Abcellera Biologics Inc is a biotech company specializing in the development of fully human monoclonal antibodies. The company was founded in 2012 by a team of scientists from the University of British Columbia, and it has since grown to become one of the world's leading developers of innovative antibody-based therapies.
Using its proprietary technology, Abcellera is able to rapidly discover and develop human antibodies against a wide range of diseases, including infectious diseases, cancer, and autoimmune disorders. The company's technology is based on a high-throughput screening platform that can analyze millions of immune cells in a matter of days, allowing for the rapid identification of promising candidates.
Abcellera's technology is particularly well-suited to the development of therapies against rapidly evolving viruses, such as COVID-19. In early 2020, Abcellera partnered with pharmaceutical company Eli Lilly to develop a monoclonal antibody treatment for COVID-19. The resulting drug, bamlanivimab, was granted emergency use authorization by the US Food and Drug Administration in November 2020.
In addition to its work on COVID-19, Abcellera is also developing therapies for a range of other diseases, including cancer and autoimmune disorders. The company has partnerships with a number of pharmaceutical companies, including Pfizer, GSK, and Novartis, and it has raised over $500 million in funding to date.
Abcellera's innovative approach to developing antibody-based therapies has earned the company numerous accolades, including being named one of the most innovative companies in biotech by Fast Company. With its cutting-edge technology and strong partnerships with the pharmaceutical industry, Abcellera is well-positioned to continue making breakthroughs in the development of novel therapeutics.
Using its proprietary technology, Abcellera is able to rapidly discover and develop human antibodies against a wide range of diseases, including infectious diseases, cancer, and autoimmune disorders. The company's technology is based on a high-throughput screening platform that can analyze millions of immune cells in a matter of days, allowing for the rapid identification of promising candidates.
Abcellera's technology is particularly well-suited to the development of therapies against rapidly evolving viruses, such as COVID-19. In early 2020, Abcellera partnered with pharmaceutical company Eli Lilly to develop a monoclonal antibody treatment for COVID-19. The resulting drug, bamlanivimab, was granted emergency use authorization by the US Food and Drug Administration in November 2020.
In addition to its work on COVID-19, Abcellera is also developing therapies for a range of other diseases, including cancer and autoimmune disorders. The company has partnerships with a number of pharmaceutical companies, including Pfizer, GSK, and Novartis, and it has raised over $500 million in funding to date.
Abcellera's innovative approach to developing antibody-based therapies has earned the company numerous accolades, including being named one of the most innovative companies in biotech by Fast Company. With its cutting-edge technology and strong partnerships with the pharmaceutical industry, Abcellera is well-positioned to continue making breakthroughs in the development of novel therapeutics.
Abcellera Biologics Inc. is a prominent biotechnology company that specializes in the innovative discovery and development of therapeutic antibodies. By leveraging cutting-edge technologies and a robust scientific framework, Abcellera efficiently identifies and isolates high-quality antibodies derived from natural immune systems. The company’s offerings can be categorized into distinct segments, products, and services, all designed to meet the growing demands of partners in the pharmaceutical and biotechnology industries.
Segments
1. Antibody Discovery and Development:
Abcellera provides an extensive suite of services that supports the entire lifecycle of therapeutic antibody development. This segment involves:
- Antibody Discovery: Utilizing advanced methodologies to identify promising candidates.
- Antibody Optimization: Enhancing the properties of candidates to improve their therapeutic efficacy.
- Preclinical Development: Preparing candidates for regulatory assessments through rigorous scientific studies and trials, ensuring that they meet necessary safety and efficacy standards.
2. Contract Research:
This segment offers tailored research services to other biotech and pharmaceutical companies. Clients benefit from Abcellera’s expertise, which includes:
- Antibody Discovery: Access to proprietary discovery methodologies, streamlining the process of finding suitable therapeutic antibodies.
- Custom Screening: Enabling tailored approaches to screen for specific antibody candidates.
- Protein Engineering: Modifying antibodies for improved function and specificity.
Products
1. Antibody Discovery Platform:
Abcellera’s proprietary platform, termed High-Throughput Single-Cell Screening (HT-SCS), represents a state-of-the-art approach to the identification of therapeutic antibodies. This platform allows for:
- Rapid and efficient isolation of antibodies from diverse immune repertoires.
- Analysis at the single-cell level, which significantly enhances the speed and specificity of antibody identification.
2. Rapid Response Platform:
The Rapid Response Platform is designed for fast-tracking the discovery and development of therapeutic antibodies, particularly in response to emerging health threats, such as infectious diseases. Features include:
- A streamlined workflow that facilitates the swift generation of antibody therapies.
- Flexibility to accommodate urgent needs arising from public health emergencies.
3. COVID-19 Response:
In response to the COVID-19 pandemic, Abcellera has dedicated resources to develop therapeutic antibodies aimed at combatting the virus. This initiative illustrates:
- The company’s commitment to addressing urgent global health issues.
- Ongoing collaborations with various stakeholders, including government and health organizations, to expedite the path to effective treatments.
Services
1. Antibody Discovery Service:
This service utilizes the HT-SCS technology to identify and isolate therapeutic antibodies from various sources, harnessing natural immune responses to generate a pool of candidates for further development.
2. Antibody Optimization Service:
Abcellera employs advanced protein engineering techniques to refine antibody candidates, focusing on enhancing their:
- Potency: Increasing therapeutic efficacy against targets.
- Stability: Ensuring the integrity and shelf-life of antibody products.
- Pharmacokinetics: Improving absorption, distribution, metabolism, and excretion characteristics.
3. Preclinical Development Service:
This service encompasses comprehensive assessments required for advancing candidates toward clinical trials. It includes:
- Conducting animal studies to evaluate safety and biological efficacy.
- Performing toxicity studies and compliance checks for regulatory submission.
4. Custom Screening Service:
This service enables partners to leverage Abcellera’s capabilities to screen extensive libraries of antibodies against tailored targets, helping to accelerate the drug discovery process.
Conclusion
Overall, Abcellera Biologics Inc. stands at the forefront of antibody discovery and development with a comprehensive array of products and services. The company’s pioneering technologies, including the HT-SCS platform and Rapid Response capabilities, paired with its commitment to innovation and collaboration, solidify its position as a leading entity in the biotechnology landscape. By providing both standard and customized services, Abcellera enables its partners to efficiently navigate the complexities of therapeutic development, particularly in critical and emergent scenarios.
Segments
1. Antibody Discovery and Development:
Abcellera provides an extensive suite of services that supports the entire lifecycle of therapeutic antibody development. This segment involves:
- Antibody Discovery: Utilizing advanced methodologies to identify promising candidates.
- Antibody Optimization: Enhancing the properties of candidates to improve their therapeutic efficacy.
- Preclinical Development: Preparing candidates for regulatory assessments through rigorous scientific studies and trials, ensuring that they meet necessary safety and efficacy standards.
2. Contract Research:
This segment offers tailored research services to other biotech and pharmaceutical companies. Clients benefit from Abcellera’s expertise, which includes:
- Antibody Discovery: Access to proprietary discovery methodologies, streamlining the process of finding suitable therapeutic antibodies.
- Custom Screening: Enabling tailored approaches to screen for specific antibody candidates.
- Protein Engineering: Modifying antibodies for improved function and specificity.
Products
1. Antibody Discovery Platform:
Abcellera’s proprietary platform, termed High-Throughput Single-Cell Screening (HT-SCS), represents a state-of-the-art approach to the identification of therapeutic antibodies. This platform allows for:
- Rapid and efficient isolation of antibodies from diverse immune repertoires.
- Analysis at the single-cell level, which significantly enhances the speed and specificity of antibody identification.
2. Rapid Response Platform:
The Rapid Response Platform is designed for fast-tracking the discovery and development of therapeutic antibodies, particularly in response to emerging health threats, such as infectious diseases. Features include:
- A streamlined workflow that facilitates the swift generation of antibody therapies.
- Flexibility to accommodate urgent needs arising from public health emergencies.
3. COVID-19 Response:
In response to the COVID-19 pandemic, Abcellera has dedicated resources to develop therapeutic antibodies aimed at combatting the virus. This initiative illustrates:
- The company’s commitment to addressing urgent global health issues.
- Ongoing collaborations with various stakeholders, including government and health organizations, to expedite the path to effective treatments.
Services
1. Antibody Discovery Service:
This service utilizes the HT-SCS technology to identify and isolate therapeutic antibodies from various sources, harnessing natural immune responses to generate a pool of candidates for further development.
2. Antibody Optimization Service:
Abcellera employs advanced protein engineering techniques to refine antibody candidates, focusing on enhancing their:
- Potency: Increasing therapeutic efficacy against targets.
- Stability: Ensuring the integrity and shelf-life of antibody products.
- Pharmacokinetics: Improving absorption, distribution, metabolism, and excretion characteristics.
3. Preclinical Development Service:
This service encompasses comprehensive assessments required for advancing candidates toward clinical trials. It includes:
- Conducting animal studies to evaluate safety and biological efficacy.
- Performing toxicity studies and compliance checks for regulatory submission.
4. Custom Screening Service:
This service enables partners to leverage Abcellera’s capabilities to screen extensive libraries of antibodies against tailored targets, helping to accelerate the drug discovery process.
Conclusion
Overall, Abcellera Biologics Inc. stands at the forefront of antibody discovery and development with a comprehensive array of products and services. The company’s pioneering technologies, including the HT-SCS platform and Rapid Response capabilities, paired with its commitment to innovation and collaboration, solidify its position as a leading entity in the biotechnology landscape. By providing both standard and customized services, Abcellera enables its partners to efficiently navigate the complexities of therapeutic development, particularly in critical and emergent scenarios.